FDA panel again rejects wider use of J&J's Xarelto

A panel of Food and Drug Administration experts again opposed expanding use of Johnson & Johnson's blood thinner Xarelto to reduce dangerous blood clots in a new group of patients, those with acute coronary artery disease.

The FDA panel on Thursday voted unanimously against broader use of the pill, saying too much information is missing from company studies to accurately gauge Xarelto's benefit. The same panel also voted against broader approval in 2012.

The FDA, which is not required to follow the panel's advice, has also twice rejected J&J's request to approve Xarelto for preventing life-threatening blood clots in patients with acute .

J&J already markets the pill for several patient groups, including those with an irregular heartbeat and those undergoing hip or knee replacement surgery.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA advisers unanimously back J&J hepatitis C drug

Oct 24, 2013

An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

Xarelto's approval expanded

Nov 05, 2012

(HealthDay)—Approval of the anti-clotting drug Xarelto (rivaroxaban) has been expanded by the U.S. Food and Drug Administration to include treating deep vein thrombosis (DVT) or pulmonary embolism.

Bayer drug unproven as stroke preventer: US

Sep 06, 2011

US regulators said Tuesday that Xarelto, a Bayer-made drug approved in July for preventing blood clots, is so far unproven for a new proposed use as a stroke preventer.

Recommended for you

FDA launches first app to identify drug shortages

7 hours ago

(HealthDay)—A mobile phone application (app) has been released to identify current drug shortages, resolved shortages, or discontinuations of drug products, according to a press release published by the ...

FDA approves first lower-cost biotech drug (Update)

9 hours ago

Federal health officials have approved the first lower-cost copy of a biotech drug to reach the U.S. market, a long-awaited milestone that could generate billions in savings for insurers, doctors and patients.

A look at the growing use of synthetic drugs

11 hours ago

In recent years, hundreds of new synthetic recreational drugs have emerged – drugs that neither the general public nor the scientific community know very much about. Many of these new synthetic drugs – ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.